Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Vistagen Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 0.24 · gapped above the open, never looked back. High/low 0.24 at 2:30 pm ET, 0.24 at 3:15 pm ET.
Vistagen Therapeutics, Inc. has 2 disclosed suppliers and 3 disclosed customers. Each one is named in an SEC filing, either Vistagen Therapeutics, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
VTGN (Vistagen Therapeutics, Inc.) has 2 disclosed suppliers and 3 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In May 2021, we entered into an Open Market Sale Agreement (the Sales Agreement) with Jefferies LLC (Jefferies) as sales agent, with respect to an at-the-market offering program (the ATM) under which we were permitted, at our option, to offer and sell, from time to time, shares of our common stock having an aggregate offering price of up to $75.0 million through Jefferies.”
FILING10-K0001628280-26-043271cik 0001411685
“We have acquired our pherine product candidates from Pherin Pharmaceuticals, Inc. (Pherin), now our wholly-owned subsidiary, and Pherin undertook research and development of such product candidates prior to our acquisitions.”
FILING10-K0001628280-26-043271cik 0001411685
“As of March 31, 2026, approximately $ 0.4 million of deferred revenue under the AffaMed Agreement remained to be recognized, which we expect to recognize in fiscal 2027.”
FILING10-K0001628280-26-043271cik 0001411685
“Under the terms of the AffaMed Agreement, we received an upfront payment of $5.0 million in August 2020.”
FILING10-K0001628280-26-043271cik 0001411685
“Approximately $1.3 million of deferred revenue under the Negotiation Agreement with Fuji Pharma also remained as of March 31, 2026.”
FILING10-K0001628280-26-043271cik 0001411685
Watchlist prices, news filtered to it, and its next report on your desk.